2 active not recruiting, 2 recruiting, 1 available, 1 terminated. 4 Phase 1, 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Active not recruiting 2, Recruiting 1, Terminated 1 |
| Phase 2 | 3 | Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 3 | 2 | Recruiting 1, Unknown 1 |
Follow Advenchen Laboratories, LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of AL8326 in Non-Small Cell Lung Cancer AL8326 tablets - Non-small Cell Lung Cancer | Phase 1 | Active not recruiting | Advenchen Laboratories, LLC | 158 | 2022-05-19 | 2025-01-27 |
| A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. AL8326 tablets, Toripalimab - Solid Tumor | Phase 1 / Phase 2 | Recruiting | Advenchen Laboratories, LLC | 228 | 2021-10-26 | 2026-02-06 |
| Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors AL3818, Nivolumab Injection - Solid Tumor, Adult, Soft Tissue Sarcoma | Phase 1 / Phase 2 | Active not recruiting | Sarcoma Oncology Research Center, LLC | 56 | 2019-10-17 | 2025-02-24 |
| Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) AL3818, Dacarbazine, AL3818 or placebo - Alveolar Soft Part Sarcoma, Leiomyosarcoma | Phase 3 | Recruiting | Advenchen Laboratories, LLC | 325 | 2017-08-15 | 2026-02-25 |
| Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) AL3818, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD) - Endometrial Carcinoma, Ovarian Carcinoma | Phase 3 | Unknown | Advenchen Laboratories, LLC | 294 | 2015-12-01 | 2023-11-08 |
| Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) AL3818 - Endometrial Cancer, Ovarian Cancer | Phase 1 / Phase 2 | Terminated | Advenchen Laboratories, LLC | 12 | 2015-11-01 | 2019-06-19 |
| Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial) AL3818 - Sarcoma,Soft Tissue, Gynecologic Cancer | Available | Advenchen Laboratories, LLC | 2022-11-28 |
Sarcoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Endometrial Neoplasms (2) · Ovarian Neoplasms (2) · Uterine Cervical Neoplasms (2) · Fallopian Tube Neoplasms (1) · Leiomyosarcoma (1) · Sarcoma, Alveolar Soft Part (1) · Sarcoma, Synovial (1) · Small Cell Lung Carcinoma (1)
anlotinib (5) · Carboplatin (1) · Dacarbazine (1) · Digoxin (1) · Midazolam (1) · Nivolumab (1) · Paclitaxel (1) · Rosuvastatin Calcium (1) · Tablets (1) · Topotecan (1) · liposomal doxorubicin (1) · toripalimab (1)
China (4) · United States (4) · Italy (2) · Spain (2) · United Kingdom (2) · South Korea (1)
LingYIng Wu (1) · Sant P Chawla, MD (1) · Xingya Li (1)